HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.

8th Edition of Cardiology World Conference

September 27-29, 2027 | London, UK

September 27 -29, 2027 | London, UK

Fibrinolytic Therapy

Fibrinolytic Therapy

Fibrinolytic therapy, also termed thrombolytic therapy, is a medical strategy designed to dissolve blood clots within the vascular system. The formation of blood clots, or thrombi, poses significant health threats by obstructing blood vessels and giving rise to conditions like pulmonary embolism or deep vein thrombosis. Utilizing fibrinolytic agents, such as tissue plasminogen activator (tPA), this intervention facilitates the breakdown of fibrin, a key protein in blood clot formation. The administration of fibrinolytic therapy is particularly time-critical, especially in acute scenarios such as pulmonary embolism, where prompt action can prevent or mitigate severe consequences. Despite its effectiveness, fibrinolytic therapy is not without risks, with potential complications including bleeding. Consequently, its application is judiciously weighed against individual patient factors and the specific clinical context. As medical research advances, ongoing exploration seeks to refine approaches, aiming to improve the safety and efficacy of fibrinolytic therapy, contributing to the continual enhancement of vascular care.

Committee Members
Speaker at Cardiology World Conference 2027 - Sekib Sokolovic

Sekib Sokolovic

ASA Hospital, Bosnia and Herzegowina
Speaker at Cardiology World Conference 2027 - James V Cireddu

James V Cireddu

Case Western University, United States
Speaker at Cardiology World Conference 2027 - Iris Panagiota Efthymiou

Iris Panagiota Efthymiou

Regent College London, United Kingdom

Submit your abstract Today

Whatsapp